Pfizer got some good news from the clinic on its novel rheumatoid arthritis drug, tofacitinib,which met its primary endpoints in a phase III study. Patients symptoms improved signifcantly and structural joint damage was slowed.
The novel drug, a JAK inhibitor, will move into an area currently dominated by TNF inhibitors like Enbrel (Amgen), Humira (Abbott) and Remicade (J&J/Merck). Pfizer will release more data at an upcoming meeting. It will be interesting to see how analysts rate this drugs revenue chances versus formidable competition in the RA arena. Regardless it is good news for Pfizer I'm sure to have one perform well in phase III.
Posted by Bruce Lehr April 15th 2011.